Trials / NCT06574997
Expanded Access Program for RP in Adults
Expanded access ended N/A Gene therapy
- Sponsor
- Ocugen
- Treatment
- OCU400
- Gene
- Not gene-specific (mentions NR2E3, RHO)
- Conditions
- Retinitis Pigmentosa
- Ages
- 18 Years to 99 Years
- Enrollment
- Not stated participants
- Started
- Not stated
- Main results expected
- Not stated
- Results posted
- Not yet
- Record last updated
- 2026-10-02
What the study is testing
This intermediate-size patient population expanded access program is to provide access to investigational product OCU400 for up to 75 patients with Retinitis Pigmentosa (RP) outside of the ongoing clinical trial Phase 3 program for patients who do not have access to alternative Food and Drug Administration (FDA)-approved products for treatment of the disease.
Where it runs
United States (5)
- Associated Retina Consultants, Phoenix, Arizona
- Advanced Research, Deerfield Beach, Florida
- Erie Retina Research, Erie, Pennsylvania
- Valley Retina Institute, McAllen, Texas
- Gundersen Health, La Crosse, Wisconsin